Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NEOTORCH
Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC
- NCT04158440 ↗
- Completed
- Shanghai Junshi Bioscience Co., Ltd.
- Deep
We haven't built an HCP commentary report on NEOTORCH (Stage II-III Non-small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NEOTORCH so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 73 | |
| Podcasts | 21 | |
| YouTube | 19 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Clinical Study on Toripalimab Combined With Platinum-Based Doublet Drug Chemotherapy for Resectable, Stage II-III, Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Stage II-III Non-small Cell Lung Cancer
- Interventions
- 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab; 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )
- Arms
- 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg) · Experimental
- 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo ) · Active comparator
- Enrollment
- 501
- Primary outcomes
- MPR rate in stage III population evaluated by BIPR
- EFS in stage III population evaluated by investigators
- MPR rate in stage II-III population evaluated by BIPR
- EFS in stage II-III population evaluated by investigators
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Start
- Apr 7, 2020
- Primary completion
- Apr 18, 2026
- Results posted
- No
- Registry record
- NCT04158440 · updated Jul 23, 2026
Publications
linked from the registry- Fang W, Wang Y, Wang W, Wu L, Sun L, Zhang P, Lu S; Neotorch Investigators; Zheng Y, Chen Q, Tan L, Yang L, Mei J, Sun X, Xu S, Shan J, Yang N, Yu D, Chen Y, Yu G, Hu X, Xing L, Wu N, Chen K, Tian H, Zhang X, Liu Y, Zhou M, Fang H, Li S, Ye M, Wu G, Cao L, Jiang J, Zhu K, Kang M, Xu H, Li X, Zhu L, Zhong A, Sun Q, Wang C, Ma H, Cai K, Zhang Y, Zhang X, Hu H, Chen J, Yang Z, Hang X, Zhang W, Huang Y, Hu J, Zhang L, Yao J, Zhang Z, Liu L, Lin D, Zhang J, Chen G, Li Y, Zhu L, Wang W, Xu J, Cao D, Zou J. Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical Trial. JAMA Surg. 2026 Jul 15:e262711. doi: 10.1001/jamasurg.2026.2711. Online ahead of print. PubMed 42455561
- Lu S, Zhang W, Wu L, Wang W, Zhang P; Neotorch Investigators; Fang W, Xing W, Chen Q, Yang L, Mei J, Tan L, Sun X, Xu S, Hu X, Yu G, Yu D, Yang N, Chen Y, Shan J, Xing L, Tian H, Zhang X, Zhou M, Fang H, Wu G, Liu Y, Ye M, Cao L, Jiang J, Li X, Zhu L, Li S, Kang M, Zhong A, Chen K, Wu N, Sun Q, Ma H, Cai K, Wang C, Lin G, Zhu K, Zhang Y, Zhang X, Hu H, Zhang W, Chen J, Yang Z, Hang X, Hu J, Huang Y, Zhang Z, Zhang L, Zhang L, Liu L, Lin D, Zhang J, Chen G, Li Y, Zhu L, Wang W, Yu W, Cao D, Keegan P, Yao S. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. JAMA. 2024 Jan 16;331(3):201-211. doi: 10.1001/jama.2023.24735. PubMed 38227033